![Nic G. Scalfarotto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nic G. Scalfarotto
Nessuna posizione attualmente
Profilo
Nic G.
Scalfarotto held former positions as Vice President-Regulatory Affairs at Momenta Pharmaceuticals, Inc., Senior Vice President-Regulatory Affairs at Aegerion Pharmaceuticals, Inc. and Kura Oncology, Inc., and VP-Regulatory Affairs & Program Management at X4 Pharmaceuticals, Inc. He obtained an undergraduate degree from Seton Hall University and a doctorate degree from Alma Mater Studiorum - Università di Bologna.
Precedenti posizioni note di Nic G. Scalfarotto
Società | Posizione | Fine |
---|---|---|
KURA ONCOLOGY, INC. | Consigliere Generale | - |
X4 PHARMACEUTICALS, INC. | Consigliere Generale | - |
AEGERION PHARMACEUTICALS, INC. | Consigliere Generale | - |
MOMENTA PHARMACEUTICALS, INC. | Consigliere Generale | - |
Formazione di Nic G. Scalfarotto
Alma Mater Studiorum - Università di Bologna | Doctorate Degree |
Seton Hall University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
X4 PHARMACEUTICALS, INC. | Health Technology |
KURA ONCOLOGY, INC. | Health Technology |
Aziende private | 2 |
---|---|
Momenta Pharmaceuticals, Inc.
![]() Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aegerion Pharmaceuticals, Inc.
![]() Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Nic G. Scalfarotto